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Summary
CBP can function as a tumor suppressor, but the mechanisms that govern oncogenesis in its absence are unknown. Here
we show that CBP inactivation in mouse thymocytes leads to lymphoma. Although CBP has been implicated in the
transactivation functions of p53, development of these tumors does not seem to involve loss of p53 activity. CBP-null
tumors show reduced levels of p27Kip1 and increased levels of cyclin E and Skp2, two oncoproteins that can promote p27Kip1
proteolysis. Reduction of p27Kip1 by introduction of a p27Kip1-null allele into CBP knockout mice accelerates lymphomagenesis
and seems to obviate the requirement for Skp2 and cyclin E upregulation. These data suggest that CBP loss mediates
lymphomagenesis in cooperation with a mechanism that reduces p27Kip1 abundance.
Introduction functions. For example, only CBP-null embryos exhibit defects
in primitive hematopoiesis (Oike et al., 1999; Yao et al., 1998).
CBP heterozygous mice, but not p300 heterozygous mice, showCBP and p300 are highly related mammalian transcriptional
coactivators that regulate gene transcription through various craniofacial and skeletal defects that are reminiscent of Rubin-
stein-Taybi syndrome (RTS) (Yao et al., 1998), a human disorderactivities (Goodman and Smolik, 2000). Both coactivators are
known to enhance gene transcription by linking sequence-spe- caused by monoallelic mutations in the CBP gene (Petrij et al.,
1995). Furthermore, CBP heterozygous mice show reduced self-cific transcription factors to the RNA polymerase II holoenzyme
(Kee et al., 1996; Nakajima et al., 1997). They also promote renewal capacity of hematopoietic stem cells, while p300 het-
erozygous mice do not (Rebel et al., 2002). Lastly, mice withgene transcription by forcing chromatin into conformations that
are more accessible to DNA binding transcription factors point mutations in the p300 KIX domain that disrupt the binding
surface for the transcription factors c-Myb and CREB showthrough the acetylation of histones (Ogryzko et al., 1996). Be-
sides histones, CBP and p300 also acetylate specific transcrip- severe hematopoietic abnormalities including anemia, B cell
deficiency, thymic hypoplasia, megakaryocytosis, and throm-tion factors. For instance, acetylation of p53 by CBP has been
shown to enhance the DNA binding ability of p53 (Gu et al., bocytosis (Kasper et al., 2002). By contrast, age-matched mice
with identical mutations in the CBP KIX domain appear essen-1997; Liu et al., 1999; Sakaguchi et al., 1998), and acetylation
of CREB has been shown to stimulate CREB-mediated gene tially normal.
Several lines of evidence suggest the involvement of CBPexpression (Lu et al., 2003).
Mice lacking CBP or p300, or that are heterozygous for both and p300 in tumor formation. CBP and p300 are at the
breakpoints of several chromosomal translocations in humanCBP and p300, typically die around day 10.5 of embryogenesis
with severe developmental retardation, reduced size, defects leukemias (reviewed in Blobel, 2000; Goodman and Smolik,
2000), and provide coactivator functions to translocation gener-in heart development, and lack of neural tube closure (Oike et
al., 1999; Yao et al., 1998). Although this confirms the notion ated fusion proteins such as NUP98-HOXA9 and MOZ-TIF2
(Deguchi et al., 2003; Kasper et al., 1999). CBP and p300 havethat CBP and p300 are functionally conserved paralogs, specific
differences in phenotype between the CBP- and p300-null em- also been implicated in the actions of viral oncoproteins such
as human T cell leukemia virus 1 (HTLV-1) Tax protein, adenovi-bryos suggest that these coactivators also have nonredundant
S I G N I F I C A N C E
The coactivator CBP supplies adaptor molecule and protein acetyltransferase functions to a multitude of transcription factors and
can contribute to the pathogenesis of human malignancies through oncogenic as well as tumor-suppressive functions. The mecha-
nisms that govern cell transformation in the absence of CBP are unknown, largely because of the embryonic lethality of CBP-null
mice. We found that conditional inactivation of CBP in thymocytes leads to lymphoma. Although the diverse and complex nature
of CBP in transcriptional regulation suggests that its loss may promote tumorigenesis by deregulation of any variety of tumor suppressor
and oncogenic pathways, this study indicates that CBP-mediated lymphomagenesis may involve a narrowly defined array of
cooperative events that includes alterations that act to reduce p27Kip1 abundance.
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rus E1A protein, simian virus (SV) 40 T antigen, and human 2-month-old CBPflox/flox and MMTV-Cre|CBPflox/flox mice with poly-
clonal antibodies against the amino or carboxy termini of CBP.papillomavirus (HPV) E6 (reviewed in Goodman and Smolik,
2000). Mutations of p300 have been found in several epithelial Virtually all thymocytes from CBPflox/flox mice were positive for
CBP (Figure 2A). In contrast, no CBP staining was seen in ap-cancers, including breast and colon. In some of these tumors,
loss of heterozygosity has been detected, suggesting that p300 proximately 65% (SD   19%, n  3) of thymocytes from
MMTV-Cre|CBPflox/flox mice (Figure 2A). Among affected thymo-may act as a tumor suppressor (Gayther et al., 2000; Muhua et
al., 1998). Although no mutations have been reported in the cytes were CD4CD8 (DN), CD4CD8 (DP), CD4CD8, and
CD4CD8 (SP) cells. Likewise, B220-positive B cells fromCBP gene of such cancers (Ozdag et al., 2002), individuals
with Rubinstein-Taybi syndrome have an increased tendency CBPflox/flox mice typically stained positive for CBP, while only
a subset of the corresponding cell types from MMTV-to develop tumors at an early age. CBP heterozygous mice
develop a variety of hematopoietic defects that become appar- Cre|CBPflox/flox mice expressed CBP (Figure 2B). There was no
detectable inactivation of CBP in bone marrow granulocytesent at about 3 months of age (Kung et al., 2000). When 18 such
mice were aged, 7 developed hematological tumors (1 lymphatic (Figure 2C). Further immunohistochemical analysis showed that
CBP protein was not expressed in the majority of mammaryleukemia, 1 myelogenous leukemia, 1 multiple myeloma, and 4
histiocytic sarcomas), with three tumors exhibiting loss at the gland epithelial cells from MMTV-Cre|CBPflox/flox females (data
not shown). Thus, CBP inactivation occurs in the expected tis-remaining wild-type CBP gene locus. Hematological malig-
nances also were found in chimeric mice derived by using sues and cell types.
CBP/ or p300/ embryonic stem cells. In this instance, one
out of the 10 adult CBP/ chimera mice developed T cell lym- High incidence of fatal T cell lymphomas
in MMTV-Cre|CBPflox/flox micephoma, whereas four out of seven p300/ chimeras developed
histiocytic sarcoma (Rebel et al., 2002). We then generated a cohort of 70 MMTV-Cre|CBPflox/flox mice
and monitored them for development of overt tumors or illAlthough these studies indicate that CBP has the features
of a tumor suppressor, the genetic changes that govern onco- health. Fifty-nine percent of these mice developed fatal T cell
lymphomas between 3 and 9 months of age (Figure 3A). Histo-genesis in its absence are unknown. Using a conditional knock-
out approach, we obtained viable mice with CBP disruption in a logical analysis of tumor sections typically showed a monoto-
nous infiltrate of lymphoblasts with numerous mitotically activevariety of tissues, including skin, thymus, salivary gland, spleen,
mammary gland, and bone marrow. We found that these mice cells (Figures 3C and 3D). Extensive lymphoblast infiltration gen-
erally occurred in nonlymphoid and lymphoid organs includingdevelop clonally derived T cell lymphomas with distinctive gene
expression signatures. We show that reduced expression of lung, liver, kidney, spleen, and lymph nodes (Figure 3E). Immu-
nohistochemical and Western blot analysis of lymphoma tissuep27Kip1, which correlates with tumor aggressiveness and poor
prognosis in many human cancers, plays a causal role in CBP- from six mice demonstrated a complete lack of CBP protein
in each of the tumors (Figures 4A and 4B). By contrast, expres-mediated lymphomagenesis, and we provide insight into the
possible mechanism by which this reduction is established. sion of p300 appeared normal (Figure 4A). Twenty-nine MMTV-
Cre|CBPflox/flox mice stayed healthy during the observation period
of 10 months, as did the 40 CBPflox/flox and 15 MMTV-Cre|CBP/Results
mice that served as control groups (Figure 3A). Analysis of the
thymuses of two long-term surviving MMTV-Cre|CBPflox/flox miceConditional inactivation of CBP in mice
To bypass the embryonic lethality caused by CBP deficiency, we for Cre-recombination showed a lack of CBP in 96% and 51% of
thymocytes, respectively, confirming that their CBP disruptiongenerated mice with a CBP conditional knockout allele (CBPflox)
(Figure 1A). The generation of these mice is described in detail frequency is similar to that of the mice that develop tumors.
We further characterized tumors from MMTV-Cre|CBPflox/floxin the Supplemental Data at http://www.cancercell.org/cgi/
content/full/5/2/177/DC1. Intercrosses of CBP/flox mice yielded mice by immunophenotyping. Tumor samples were primarily
CD4, CD8, and CD3, matching the cell surface marker profileCBP/, CBP/flox, and CBPflox/flox offspring at the Mendelian ratio
(Figure 1B). CBPflox/flox mice were indistinguishable from their of late cortical thymocytes (see Figure 4D and Supplemen-
tal Table S1 at http://www.cancercell.org/cgi/content/full/5/2/wild-type littermates and had a normal lifespan, indicating that
the activity of the floxed CBP allele was similar to that of the 177/DC1). Lymphoblasts from these tumors generally ex-
pressed remarkably high levels of the IL-2 receptor  chain.wild-type allele.
To test whether CBP exerts tumor suppression activity, we One of 15 tumors analyzed exhibited a CD4, CD8, and CD3
mature T cell profile (Supplemental Table S1). All tumors werecrossed CBPflox/flox mice with MMTV-Cre transgenic mice that
induce deletion of loxP-flanked alleles to mammary and salivary negative for the B cell marker B220. Next, DNA was isolated
glands, skin, and certain hematopoietic cells (Wagner et al., from 9 tumors and analyzed for T cell receptor (TCR)  chain
1997). MMTV-Cre|CBPflox/flox mice were born alive and showed gene rearrangements by Southern blot hybridization to a TCR
no overt abnormalities. We verified Cre-mediated deletion of C2 probe. Each of the tumors showed one or two discrete
exon 9 in various tissues from 2-month-old MMTV-Cre|CBPflox/flox bands indicative of the clonal origin of the lymphomas (Fig-
mice by Southern blot analysis (Figure 1C). As expected, exten- ure 4C).
sive disruption of CBP occurred in mammary gland, salivary
gland, skin, and hematopoietic cells in bone marrow, thymus, Altered thymocyte development
in MMTV-Cre|CBPflox/flox miceand spleen, while no detectable disruption occurred in skeletal
muscle, testis, brain, lung, liver, kidney, and heart. To define possible effects of CBP disruption on thymocyte de-
velopment, we collected thymuses from preleukemic 8-week-To verify that Cre-recombination created a null allele (CBP),
we stained thymus, lymph node and bone marrow cells from old MMTV-Cre|CBPflox/flox mice and analyzed their thymocytes
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Figure 1. Generation of CBP conditional knock-
out mice
A: Schematic of the endogenous CBP locus, the
targeting vector, and various mutant CBP alleles.
LoxP recombination sites used to generate the
CBPflox allele are shown as triangles. EcoRI restric-
tion sites used for Southern blot identification of
mutant CBP alleles are indicated, as is the exter-
nal hybridization probe. Abbreviations: NEO,
neomycin resistance gene; HSV tk, herpes sim-
plex virus thymidine kinase gene.
B: Southern blot of EcoRI-digested tail DNA from
CBP/, CBP/flox CBPflox/flox mice. Sizes of the bands
representing the CBP and CBPflox alleles are indi-
cated. The genotypes are displayed above the
lanes.
C: Southern blot analysis of EcoRI-digested DNA
from various tissues of an 8-week-old MMTV-Cre|-
CBPflox/flox female mouse (the testis sample was
from a male mouse of the same genotype). The
sizes of the bands representing the CBPflox and
CBP alleles are indicated.
by flow cytometry. There were on average 2  108 thymocytes tylate p53 at specific sites (Ito et al., 2001; Sakaguchi et al.,
1998). The acetylation seems to play a role in stabilization ofper MMTV-Cre|CBPflox/flox mouse (SD 0.3 108, n 4 mice)
versus 1.7  108 thymocytes per CBPflox/flox mouse (SD   p53 through inhibition of its ubiquitination by Mdm2 (Ito et al.,
2001; Li et al., 2002). Because most p53-null mice, like MMTV-0.6  108, n  4 mice). CD4 and CD8 staining of thymocytes
confirmed that all subpopulations of thymocytes were present Cre|CBPflox/flox mice, develop T cell lymphoma, we hypothesized
that loss of CBP may contribute to tumorigenesis through inacti-in MMTV-Cre|CBPflox/flox mice (Figure 4D). The percentages of
DN and CD4-SP thymocytes were comparable in MMTV-Cre| vation of p53 tumor suppressor functions (Giordano and Avan-
taggiati, 1999). To test this idea, we performed two experimentsCBPflox/flox and CBPflox/flox mice. However, the percentages of the
CD8-SP thymocytes were significantly increased in MMTV-Cre| involving ionizing radiation to activate p53. First, we exposed
20 MMTV-Cre|CBPflox/flox and 9 CBPflox/flox mice to a 1 Gray (Gy)CBPflox/flox mice compared to CBPflox/flox mice (21%  9% [n 
8] versus 2%  0.5% [n  5]). Concomitantly, the percentages dose of whole body 	 irradiation at 14 and 21 days of age and
monitored them for the development of tumors. We verifiedof DP thymocytes were significantly reduced in MMTV-Cre|
CBPflox/flox mice compared to CBPflox/flox mice (61%  9% [n  by immunolabeling that a substantial proportion of thymocytes
lacked CBP at the age of irradiation (55%  7, n  3). Previous8] versus 82%  2% [n  5]). These data suggest that the cell
fate decision process in DP thymocytes may require specific work has shown that irradiation of pre-weanling p53/ mice
with 1 Gy of ionizing irradiation decreases the tumor latencyCBP functions that cannot be substituted by p300, or may
depend on a certain amount of total CBP/p300 protein. from a median of 21 weeks to 14–15 weeks of age (Kemp et
al., 1994). Thus, if loss of CBP results in functional inactivation
of p53’s tumor suppression activity, then one would expect toCBP-null tumors retain p53 responses to DNA damage
find MMTV-Cre|CBPflox/flox mice susceptible to radiation-inducedNumerous studies have highlighted a role of CBP and p300 in
T cell lymphomagenesis. As shown in Figure 5A, ionizing irradia-the p53 signaling pathway (reviewed by Goodman and Smolik,
tion did not decrease the latency for T cell tumor development2000; Grossman, 2001). CBP and p300 physically interact with
p53 and modulate p53 transcriptional activity (Avantaggiati et in MMTV-Cre|CBPflox/flox mice, suggesting that the p53 response
to 	 irradiation-induced DNA damage is intact in the absence ofal., 1997; Gu et al., 1997; Lill et al., 1997). In response to DNA
damage or other stress-inducing agents, CBP and p300 ace- CBP. In the second experiment, we measured the p53 response
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Figure 2. Cre recombinase activity in hemato-
poietic cells of MMTV-Cre|CBPflox/flox mice
A–C: Representative confocal images of cells
from various hematopoietic tissues of 8-week-old
CBPflox/flox and (preleukemic) MMTVCre|CBPflox/flox
mice stained for various proteins. A: Thymocytes
triple-labeled with CD8, CD4, and CBP antibod-
ies. Note that the majority of MMTVCre|CBPflox/flox
thymocytes are negative for CBP and that DN,
DP, and both types of SP thymocytes were
among the negative cells. B: Lymph node cells
double-labeled with B220 and CBP. Arrowheads
mark B220-positive B cells that lack CBP. C: Bone
marrow cells double-stained for myelocyte
marker Gr-1 and CBP. Note that no significant
Cre-mediated inactivation occurs in myelo-
cytes.
following irradiation of CBP-null tumors. Lymphomas were har- to radiation-induced DNA damage. After DNA damage, p53
normally activates a number of transcriptional targets, includingvested from MMTV-Cre|CBPflox/flox mice (n  7) and cell suspen-
sions from these tumors were treated with 5 Gy of ionizing the cyclin-dependent kinase inhibitor p21Waf/Cip1. Indeed, the level
of p21Waf/Cip1 increased in both normal and tumor cells, withirradiation. For comparison, thymocytes from CBPflox/flox mice
were treated similarly. p53 protein levels, which were low before tumor cells showing an even more robust increase than control
cells (Figure 5B). Irradiated preleukemic MMTV-Cre|CBPflox/floxirradiation, as expected, showed a strong increase at 4 hr after
treatment for both tumor cells lacking CBP and control thymo- thymocytes showed levels of p21Waf/Cip1 induction that were simi-
lar to those of control thymocytes. Moreover, when CBP-nullcytes (Figure 5B). By 8 hr after irradiation, p53 protein levels
were decreased in both tumor and control cells. These results tumor cells were analyzed for p53-dependent radiation-induced
apoptosis by standard methods (Lowe et al., 1993), similar deathindicate that CBP is dispensable for p53 induction in response
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Figure 3. MMTV-Cre|CBPflox/flox mice develop lethal T cell lymphomas
A: Kaplan-Meier tumor-free survival curve of MMTV-Cre|CBPflox/flox, CBPflox/flox,
and MMTV-Cre|CBP/ mice. The median tumor-free survival period of
MMTV-Cre|CBPflox/flox mice was 24 weeks.
B: Gross morphology of a representative T cell lymphoma (arrow).
C–E: Histopathology of tumors from moribund MMTV-Cre|CBPflox/flox mice (he-
matoxylin and eosin-stained paraffin sections). C: Large macrophages with
nuclear debris of lymphocytes in their cytoplasm (asterisks) embedded in
uniform populations of highly mitotic thymic lymphoblasts (arrows). D: Detail
of mitotic lymphoblasts (arrows). E: Lymphoma cells (arrows) infiltrated in
kidney tissue (G marks a glomerulus and a renal tubule).
Figure 4. Lymphomas consist of mono- or oligoclonal populations of DP thy-
rates were observed in normal thymocytes and cells from CBP- mocytes that lack CBP
null tumors (data not shown; n  2 independent tumors). A: Representative confocal images of cells from a wild-type thymus and a
Next, we employed DNA microarray technology to generate T cell lymphoma stained with CBP antibodies and Hoechst.
A: Confocal images of cells from a T cell lymphoma stained with p300expression profiles of two p53-null and three CBP-null tumors
antibodies and Hoechst, demonstrating that CBP disruption does not inter-(all five tumors were DP). Hierarchical clustering analysis of the
fere with p300 expression.resulting gene expression data grouped the p53-null and CBP- B: Analysis of lymphomas from distinct MMTV-Cre|CBPflox/flox mice for CBP
null tumors in two clearly distinguishable branches, suggesting protein levels by Western blotting. 100 
g of total protein extract from each
tumor was used in the analysis. For probes, we used a rabbit antibodythat their transformation pathways were distinct (Figure 5D). At
against CBP(C-20) or anti-CBP(A-22).least 60 genes were differentially expressed more than 2-fold
C: SacI-digested genomic DNAs extracted from T cell lymphomas analyzedbetween the two tumor types (p  0.01 by two-tailed t test).
by Southern blot hybridization to the TCR C2 probe. All MMTV-Cre|CBPflox/flox-
These results strongly suggest that the tumorigenic mecha- derived lymphomas tested show one or two discrete rearranged fragments,
nisms operating in the two lymphoma types were dissimilar and reflecting clonal expansion.
D: CD4/CD8 FACS profiles of thymocytes from 8-week-old CBPflox/flox andreinforced the notion that loss of CBP promotes tumorigenesis
MMTV-Cre|CBPflox/flox mice, and cells from tumors of two moribund MMTV-through a mechanism that does not involve p53 inactivation.
Cre|CBPflox/flox mice.
Disruption of p53 accelerates tumorigenesis
in CBP conditional knockout mice
Although CBP does not seem to play a critical role in the p53-
dependent DNA damage pathway, other pathways that regulate
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Figure 5. Loss of CBP does not abolish p53 tumor
suppression activity
A: Survival curves of irradiated MMTV-Cre|
CBPflox/flox, irradiated CBPflox/flox, and nonirradiated
MMTV-Cre|CBPflox/flox mice.
B: Analysis of p53 and p21Waf1/Cip1 protein levels in
T cell tumor cells from MMTV-Cre|CBPflox/flox and
p53/ mice and in thymocytes from 8-week-old
CBPflox/flox and MMTV-Cre|CBPflox/flox mice before
and after 5 Gy of ionizing irradiation. Results
shown are representative for 3 experiments in
which tumor cells from 7 moribund MMTV-Cre|
CBPflox/flox mice were evaluated.
C: Survival curves of MMTV-Cre|CBPflox/flox, MMTV-
Cre|CBPflox/flox;p53/, and p53/ mice. All MMTV-
Cre|CBPflox/flox;p53/ mice died of T cell lym-
phoma before the age of 16 weeks (lower line).
By contrast, 93% of MMTVCre|CBPflox/flox mice (up-
per line) and 57% of p53/ mice (middle line)
were alive at 16 weeks.
D: Hierarchical heat map of genes differentially
expressed an average more than 2-fold be-
tween CBP-null (CBP) and p53-null (p53) T cell
lymphomas. Only probe sets that were identified
as differentially expressed between the two tu-
mor types by two-tailed t test were included (p
0.01). Data is presented as a signed ratio be-
tween the expression signal for individual tumors
and the mean signal for two normal CBPflox/flox
thymuses (green  6-fold, red  6-fold).
p53 activity could still be disrupted. To test for this possibility, DNA microarray analysis of preleukemic thymocytes
To identify gene deregulations that might explain why CBP-nullwe crossed CBP conditional knockout mice onto a p53-null
thymocytes are predisposed to tumor formation, we generatedbackground and observed them for tumor formation. If com-
expression profiles of preleukemic DP thymocytes by DNA mi-bined loss of CBP and p53 tumor suppression pathways would
croarray analysis. DP thymocytes were selected for analysissignificantly decrease tumor latency, then this would strengthen
because 90% of the CBP-null tumors originated from thisthe idea that p53 tumor suppression activity remains intact
cell type. We collected thymuses of two 8-week-old MMTV-in the absence of CBP. We produced cohorts of MMTV-
Cre|CBPflox/flox and two CBPflox/flox mice, purified DP thymocytesCre|CBPflox/flox;p53/ and CBPflox/flox;p53/ mice and observed
by FACS (40%–65% of the sorted cells from the MMTV-
them daily for development of tumors or ill health. The CBPflox/flox;
Cre|CBPflox/flox mice lacked CBP), and isolated RNA from each
p53/ mice developed T cell lymphomas with a median tumor- of the four samples for hybridization to AFFY_MOE430A chips
free survival period of 16 weeks (Figure 5C). By contrast, MMTV- (containing 14,092 genes). By cluster analysis, we identified a
Cre|CBPflox/flox;p53/ developed T cell lymphomas with a much set of eight genes whose levels were reproducibly changed 2
shorter median tumor-free survival period of 12 weeks, with fold by the loss of CBP (see Supplemental Table S2 at http://
none of the animals surviving beyond 16 weeks. PCR genotyp- www.cancer cell.org/cgi/content/full/5/2/177/DC1), but it pro-
ing revealed that all tumors from MMTV-Cre|CBPflox/flox;p53/ vided no clues about the events that might initiate lympho-
mice were homozygous for the Cre-recombined CBP-null allele magenesis in CBP-deficient thymocytes. This result indicates
that loss of CBP may act to increase the susceptibility of tumor(data not shown).
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development by subtle deregulation of a large number of targets
rather than by severely impairing the activities of a small number
of cancer-causing genes. Another possibility is that CBP loss
may only exert its tumor-promoting effect after a CBP-null cell
has undergone a mutation in a particular cancer-critical gene.
CBP acts synergistically with p27Kip1
in tumor suppression
The time to onset of tumor formation and the clonal derivation
of the tumors indicated that cooperative events are implicated
in the development of lymphoma in CBP conditional knockout
mice. Genetic events that disrupt key regulators of G1 progres-
sion are found in most human cancers, including lymphomas
(Erlanson et al., 1998). This prompted us to analyze tumor sam-
ples from MMTV-Cre|CBPflox/flox mice for altered expression of
such regulators by Western blot analysis. We found that cyclin
D1, cyclin A, CDK2, and CDK4 were all expressed at similar
levels in tumors and normal thymuses (data not shown). How-
ever, with 100% penetrance, p27Kip1 was expressed at substan-
tially lower levels in tumor cells (Figure 6A, lanes 3–8; n  15
mice) than in thymocytes from CBPflox/flox mice (lanes 1 and 2;
n 4 mice), thymocytes from preleukemic MMTV-Cre|CBPflox/flox
mice (Figure 6B and C; n  4 mice), and thymocytes from
CBPflox/flox mice that were stimulated with the mitogen PHA (Fig-
ure 6B, lanes 8–10; n  3 mice, see also Supplemental Experi-
mental Procedures and Supplemental Figure S1 at http://www.
cancercell.org/cgi/content/full/5/2/177/DC1). In addition, cyclin E
levels were always much higher in tumor cells (Figure 6A, lanes
3–8) than in the various control thymocytes (Figure 6A and 6B).
Importantly, low p27Kip1 and high cyclin E levels have been found
in a variety of human cancers, either alone or in combination,
and correlate with reduced long-term survival (Catzavelos et
al., 1997; Loda et al., 1997; Porter et al., 1997).
The fact that a substantial proportion of CD4CD8 lympho-
mas induced by Moloney murine leukemia virus (MuMLV) retain
high levels of p27Kip1 protein (Martins and Berns, 2002) suggests
that p27Kip1 is not simply downregulated due to increased prolif-
eration of tumor cells compared to normal thymocytes. To es-
Figure 6. Loss of CBP synergizes with reduced expression of p27Kip1 in T celltablish whether the reduced expression of p27Kip1 in CBP-null
lymphomagenesis
tumors might be a deregulation that cooperates with CBP loss
A and B: Western blot of p27Kip1 and cyclin E protein levels in lymphomas from
in T cell lymphomagenesis, CBP conditional knockout mice moribund MMTV-Cre|CBPflox/flox mice, thymocytes from 8-week-old CBPflox/flox
were interbred with p27Kip1 knockout mice to generate MMTV- and (healthy) MMTV-Cre|CBPflox/flox mice, and thymocytes from 10-week-old
CBPflox/flox mice that were cultured for 68 hr in the presence () or absenceCre|CBPflox/flox;p27Kip1/ mice, which were monitored for tumor
() of the mitogen PHA (20 
g/ml). Proliferation induction by PHA wasformation (disruption of a single p27Kip1 allele is known to cause
verified by 3H thymidine incorporation (see Supplementary Figure S1 at
decreased p27Kip1 protein expression [Fero et al., 1998]). MMTV- http://www.cancercell.org/cgi/content/full/5/2/177/DC1). 30 
g of total
protein extract was loaded per lane.Cre|CBPflox/flox;p27Kip1/ mice developed T cell lymphomas with
C: Representative confocal images of thymocytes from an 8-week-olda median tumor-free survival period of 12–13 weeks (Figure 6D;
healthy MMTVCre|CBPflox/flox mouse double-labeled for p27Kip1 and CBP, or
p  0.0001 by the logrank test). For MMTV-Cre|CBPflox/flox mice cyclin E and CBP. Note that p27Kip1 and cyclin E protein levels are similar in
on a similar genetic background, the median tumor-free survival CBP-positive and negative cells prior to tumor formation.
D: Survival curves of MMTV-Cre|CBPflox/flox and MMTV-Cre|CBPflox/flox;p27Kip1/period was 24 weeks. Consistent with previously reported stud-
mice. The median tumor free-survival period of MMTV-Cre|CBPflox/flox;ies (Fero et al., 1996, 1998), a cohort of 15 p27Kip1/ control mice
p27Kip1/ mice was significantly decreased compared to MMTV-Cre|
showed no T cell lymphoma development (data not shown). CBPflox/flox mice on a similar genetic background (p  0.0001 by the logrank
test).Western blots showed that tumor lysates from MMTV-Cre|
CBPflox/flox;p27Kip1/ mice contained p27Kip1 protein, indicating
that there was no loss of the wild-type p27Kip1 allele during
tumorigenesis (data not shown). Taken together, the above data
indicate a causal link between p27Kip1 insufficiency and tumor
progression in CBP conditional knockout mice.
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Abnormal gene transcription and protein degradation
downregulate p27Kip1 in CBP-null tumors
We investigated the mechanism of p27Kip1 downregulation dur-
ing CBP-mediated lymphomagenesis, and first focused on
Skp2. This F box protein normally accumulates in G1 phase and
targets p27Kip1 molecules that have been phosphorylated by
cyclin E/Cdk2 for ubiquitin-mediated degradation at the G1/S
transition (Carrano et al., 1999). High levels of Skp2 are known
to enhance p27Kip1 degradation (Blain et al., 2003; Bloom and
Pagano, 2003), which prompted us to test for the possibility that
Skp2 overexpression might be involved in the downregulation of
p27Kip1 during CBP-mediated lymphomagenesis. As shown in
Figure 7A, Skp2 protein levels were always higher in tumors
from MMTV-Cre|CBPflox/flox mice (lanes 3–8; n  9 mice) than in
thymocytes from CBPflox/flox mice (lanes 1 and 2; n  4 mice) or
healthy 8-week-old MMTV-Cre|CBPflox/flox mice (data not shown).
We reasoned that if this increase participates in CBP-mediated
lymphomagenesis through downregulation of p27Kip1, one would
not expect to find it in tumors from MMTV-Cre|CBPflox/flox;
p27Kip1/ mice. Indeed, high Skp2 levels were not seen in the
tumors that we collected from four MMTV-Cre|CBPflox/flox;
p27Kip1/ mice (Figure 7B, lanes 6–9). In addition, increased
expression of cyclin E, which characterizes MMTV-
Cre|CBPflox/flox tumors (Figure 6A) and which might act to enhance
p27Kip1 phosphorylation and subsequent Skp2-mediated degra-
dation (Blain et al., 2003), was not consistently seen in tumors
from MMTV-Cre|CBPflox/flox;p27Kip1/mice (Figure 7B). The data
suggest that the increases in Skp2 and cyclin E may act coordi-
nately to induce unscheduled S phase entry through p27Kip1
downregulation.
To confirm that the mechanism of p27Kip1 reduction in CBP-
null tumors involves proteosome-dependent protein degrada-
tion, we cultured MMTV-Cre|CBPflox/flox tumor cells for 6 hr in
the presence or absence of the proteosome inhibitor MG132
(25 
M) and then measured p27Kip1 levels by Western blot analy-
Figure 7. Negative regulators of p27Kip1 are expressed at increased levels in
sis. As shown in Figure 7C (lanes 3–6), MG132-treated tumor CBP-null tumors
cells had considerably higher p27Kip1 levels compared to their A: Expression of Skp2 in thymocytes from two 8-week-old CBPflox/flox mice
nontreated counterparts. As expected, normal thymocytes, (lanes 1 and 2), and tumors from six individual MMTV-Cre|CBPflox/flox mice.
Blots were respectively probed with Skp2 (SKP2-2B12, and actin antibody.which have low p27Kip1degradation activity (Latres et al., 2001),
B: Levels of Skp2 and cyclin E in lymphomas from MMTV-Cre|CBPflox/flox andshowed similar p27Kip1 levels in the presence or absence of
MMTV-Cre|CBPflox/flox;p27Kip1/ mice (the tumor in lane 8 showed cyclin EMG132 (lanes 1 and 2).
signal upon extended exposure of the blot).
We next tested the possibility that reduced gene transcrip- C: Measurements of proteosome-dependent p27Kip1 degradation in tumor
tion contributed to p27Kip1 downregulation in CBP-null tumors cells from two MMTV-Cre|CBPflox/flox mice and thymocytes from a CBPflox/flox
control mouse using the proteosome inhibitor MG132.by quantitative (Q)RT-PCR analysis. p27Kip1 mRNA levels were
D: Analysis of p27Kip1 and c-Myc gene expression levels QRT-PCR in thymo-on average about 2-fold lower in tumor cells than in thymocytes
cytes from 8-week-old CBPflox/flox (n  2) and (healthy) MMTV-Cre|CBPflox/flox
from 8-week-old CBPflox/flox or MMTV-Cre|CBPflox/flox mice (Figure mice (n  2) and tumor cells from MMTV-Cre|CBPflox/flox mice (n  3) and
7D). Together, our data suggest that downregulation of p27Kip1 MMTV-Cre|CBPflox/flox;p27Kip1/ mice (n  4).
levels in CBP-null tumors is established by decreased p27Kip1
gene transcription (and/or mRNA stability) and increased pro-
teosome-dependent degradation of p27Kip1 protein.
1993; Martins and Berns, 2002). Validation experiments con-
Protooncogenes Notch1, Bmi-1, and Myc firmed that Notch1 protein levels were substantially increased
are upregulated in CBP-null tumors in 5 out of 6 tumors analyzed (Figure 8A, lanes 3–8; n  6
By comparing the transcriptional profiles of three CBP-null tu- independent mice). Several target genes that are regulated by
mors to those of two control thymocytes, we identified 64 genes Notch1, such as Adam9, Dtx1, and Hes-1, were expressed
whose expression was changed more than 2-fold: 34 genes at considerably higher levels in tumors from CBP conditional
knockout mice than in thymocytes from CBPflox/flox mice orwere decreased in activity, and 30 genes were more actively
transcribed in tumor cells (Figure 8A). The latter group contained healthy 8-week-old MMTV-Cre|CBPflox/flox mice (see Figure 8B).
This result further confirmed that Notch1 activity increased dur-the transcription factors Notch1, Bmi-1, and Myc, all of which
can cause T cell lymphomas in mice when ectopically expressed ing CBP-mediated tumorigenesis. In addition, Western blot ex-
periments confirmed that Bmi-1 protein levels were substantially(Alkema et al., 1997; Fowlkes and Robey, 2002; Haupt et al.,
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Figure 8. Expression signature of CBP-null tumors
A: Expression profiles of genes that were 2-fold changed in CBP-null tumors (n  3) versus control (CBPflox/flox) thymuses (n  2). Data is presented as base
2 logarithm of signal values (green  signal value of 49, red  signal value of 54,000). Genes typed in red font were confirmed by QRT-PCR or Western
blotting. We note that Skp2 probes were not on the U74 GeneChip, whereas p27Kip1 probesets were scored absent by the Affymetrix software.
B: Confirmation of increased Notch1 expression in CBP-null tumors by Western blotting. Notch1-mN1A antibody, which detects both the full-length protein
(Notch1) and the active intracellular domain of Notch1 (IC Notch1), was used as probe.
C: Confirmation of Notch1-target genes by QRT-PCR.
D: Confirmation of Bmi-1 overexpression in CBP-null tumors by Western blotting.
higher in 8 out of 9 lymphomas tested (lanes 5–7) compared to Discussion
thymocytes from CBPflox/flox mice (lane 1; n  3 thymuses) or
By the use of CBP conditional knockout mice, we show thathealthy 8-week-old MMTV-Cre|CBPflox/flox mice (lanes 2–4; n 
inactivation of CBP in the thymus leads to formation of lethal3 thymuses). Although Bmi-1 has been shown to downregulate
T cell lymphomas between 3 and 9 months of age with 60%p16Ink4a gene transcription (Jacobs et al., 1999), we found no
penetrance. The remarkably similar immunophenotypes andevidence for reduced expression of p16 and p19Arf in CBP-
pathogenic transcriptional profiles of these lymphomas sug-null tumors by expression profiling, QRT-PCR, or Western blot
gested that CBP loss acts to promote tumorigenesis in coopera-analysis (data not shown). QRT-PCR analysis for Myc showed
tion with a narrowly defined array of genetic changes. Further
that the expression of this protooncogene was on average analyses indicated that downregulation of the tumor suppressor
2- to 3-fold higher in tumors from MMTV-Cre|CBPflox/flox mice p27Kip1 is a key determinant of CBP-mediated lymphomagene-
than in thymocytes from CBPflox/flox or healthy MMTV-Cre|CBPflox/flox sis, and that key regulators of p27Kip1 proteosomal degradation
mice (Figure 7D). Taken together, these results demonstrate are overexpressed in CBP-null tumors.
that the protooncogenes Notch1, Bmi-1, and Myc are overex- Because p53-null mice develop fatal T cell lymphomas and
pressed in most CBP-null tumors, and suggest that their deregu- because a multitude of studies have implicated CBP and p300
in the transactivation functions of p53 (Goodman and Smolik,lation might play a role in CBP-mediated lymphomagenesis.
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2000; Grossman, 2001), we initially hypothesized that CBP loss displayed several abnormalities that are consistent with in-
creased p27Kip1 protein degradation. Of these, the upregulationleads to tumor formation through inactivation of p53. However,
five distinct lines of experimental evidence indicate that there of Skp2, a key component of the SCF ubiquitin ligase complex
that targets p27Kip1 for destruction by the proteosome (Carranois no loss of p53 tumor suppression activity in tumors that
lack CBP. First, asymptomatic mutant mice with a substantial et al., 1999), was perhaps the most prominent one. Skp2 has
oncogenic properties (Latres et al., 2001), and is overexpressedproportion of thymocytes lacking CBP protein exhibited no in-
creased susceptibility to radiation-induced lymphomagenesis, in many human cancers, including lymphomas, where its level
of expression seems to correlate with the grade of malignancyimplying that proper p53-mediated DNA repair and apoptosis
occurred despite CBP deficiency. In fact, irradiated conditional and inversely with p27Kip1 levels (reviewed in Blain et al., 2003).
A second abnormality was the upregulation of cyclin E. Thisknockout mice showed a somewhat reduced latency compared
to their nonirradiated counterparts (see Figure 5A). The basis cyclin normally accumulates in G1 phase and targets p27Kip1
protein for ubiquitin-mediated degradation by phosphorylationof this difference is unclear. One possible explanation is that it
is caused by radiation-induced cell death, which normally oc- on tyrosine 187, and when expressed at high levels, it seems
to increase p27Kip1 phosphorylation and degradation (reviewedcurs in thymocytes with an intact p53 response to DNA damage
(Lowe et al., 1993). Since CBP-null tumors are clonally derived, by Blain et al., 2003; Bloom and Pagano, 2003). CBP conditional
knockout mice in which p27Kip1 levels were lowered geneticallythe reduction in total thymocyte number in irradiated mice may
outweigh the risk of radiation-induced tumors. Second, cells by the introduction of a p27Kip1-null allele produced tumors with
relatively low Skp2 and cyclin E levels, a finding that supportsfrom tumors of moribund CBP conditional knockout mice re-
sponded to ionizing irradiation with p53 stabilization and induc- the view that increases in Skp2 and cyclin E stimulate p27Kip1
degradation during CBP-mediated lymphomagenesis (Figuretion of p21Waf/Cip1, suggesting that the p53 response to DNA
damage was intact (Figure 5B). Third, radiation-induced apopto- 7B). Myc has also been implicated in ubiquitinated-mediated
degradation of p27Kip1 (Muller et al., 1997; O’Hagan et al., 2000).sis was similar in cells from CBP-null tumors and thymocytes
from control mice. Fourth, DNA microarray analysis revealed However, in CBP-null tumors, Myc overexpression may not be
linked to p27Kip1 degradation, because Myc levels remaineddistinctive gene expression profiles for p53-null and CBP-null
tumors, with at least 60 genes differentially expressed more than highly increased in tumors from MMTV-Cre|CBPflox/flox;p27Kip1/
mice (Figure 7D). This interpretation is further supported by a2 fold, suggesting that the tumorigenic mechanisms operating in
the two lymphoma types were distinct (Figure 5D). Fifth, double study from Martins and Berns in which p27Kip1 loss is shown to
synergize with Myc overexpression in murine lymphomagenesismutant mice lacking both CBP and p53 developed T cell lym-
phomas with significantly shorter latencies than mice with only (Martins and Berns, 2002).
Two additional oncoproteins, Notch1 and Bmi-1, are ex-CBP- or p53-null mutations (Figure 5C). This cooperative effect
argues that the tumor suppression activities of CBP and p53 pressed at very high levels in almost all CBP-null tumors. Given
that overexpression of each of these proteins in mouse thymo-in T cell lymphomagenesis are not redundant. We note that
although p53 loss can cooperate with CBP loss, lymphomagen- cytes has been shown to result in the development of T cell
lymphomas (Alkema et al., 1997; Fowlkes and Robey, 2002;esis in CBP conditional single knockout mice is unlikely to in-
volve such cooperation, as both preleukemic and fully trans- Haupt et al., 1993), it is tempting to speculate that they may
play an active role in CBP-mediated lymphomagenesis. Be-formed thymocytes seem to have conserved p53 activity. The
simplest explanation for finding that key p53 functions appear cause there was no detectable upregulation of Notch1 and
Bmi-1 in thymocytes from preleukemic CBP conditional knock-to be intact in CBP-null thymocytes would be that CBP and
p300 are fully redundant for their functions in p53-dependent out mice, it seems that their role, if any, would be late rather than
early in the transformation process. It will be of great interest totranscription and that p300 levels are sufficiently high to deliver
these functions to p53. Alternatively, it is possible that CBP and further investigate whether Notch1, Bmi-1 and Myc act synergis-
tically with CBP loss by crossing CBP conditional knockoutp300 functions are distinct in thymocytes, with p300 exclusively
providing adaptor molecule and protein acetyltransferase func- mice with transgenics overexpressing these genes.
In conclusion, our study illustrates that loss of the versatiletions to p53. Testing for this possibility would require p300
conditional knockout mice, given the embryonic lethal pheno- transcriptional coactivator CBP leads to tumors with a distinc-
tive pathogenic expression signature that includes several can-type associated complete p300 disruptions (Yao et al., 1998).
There are also likely to be CBP-independent mechanisms impor- cer-critical genes that are often deregulated in human lympho-
mas and associated with poor prognosis. Whether CBP istant for p53 function.
Our findings suggest that p27Kip1 insufficiency is a key coop- disrupted or functionally inactivated in human lymphomas re-
mains to be investigated. The expression signature reportederative event in CBP-mediated lymphomagenesis, and show
that the mechanism of p27Kip1 reduction in CBP tumors seems here might be a useful guide in the identification of cancers
with CBP loss. In addition, the availability of CBP conditionalto involve decreased gene transcription and increased protein
knockout mice will provide a novel tool for further evaluation ofdegradation. It seems unlikely that the observed reduction in
the role of CBP in the development of cancer and for preclinicalp27Kip1 mRNA levels is a direct consequence of CBP loss, be-
therapeutic studies.cause both p27Kip1 mRNA and protein levels appeared normal
in preleukemic thymocytes from CBP conditional knockout mice
Experimental procedures(Figures 6B, 6C, and 7D). However, one possibility is that the
Myc oncoprotein, which is overexpressed in CBP-null tumors
Generation of CBP conditional knockout
(Figures 7D and 8), and which has been reported to bind to and and compound mutant mice
repress the p27Kip1 gene promoter (Yang et al., 2001), causes CBP conditional knockout mice were generated as described in detail in the
Supplemental Data at http://www.cancercell.org/cgi/content/full/5/2/177/the transcriptional reduction. We found that CBP-null tumors
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DC1. These mice were bred to MMTV-Cre transgenic mice (Wagner et al., Western blot analysis. For analysis of p27Kip1 proteolysis, cell suspensions
were cultured in the presence of 25 
M MG132 (Boston Biochemical).1997). Male MMTV-Cre|CBP/flox mice were bred with CBPflox/flox females to
produce MMTV-Cre|CBPflox/flox mice. MMTV-Cre|CBPflox/flox;p53/ and
DNA microarray analysisCBPflox/flox;p53/ animals were generated by breeding p53/ mice to MMTV-
Thymus or tumor masses were collected from mice and homogenized forCre|CBPflox/flox mice. MMTV-Cre|CBPflox/flox;p27Kip1/ mice were produced by
total RNA isolation with TRIzol reagent (Life Technologies). RNA samplesbreeding p27Kip1/ mice (Fero et al., 1996) to MMTV-Cre|CBPflox/flox mice. All
were further processed for hybridization to AFFY_U74A or AFFY_MOE430Amice used in the tumor-free survival studies described in this report were
Genechips (Affymetrix, Santa Clara) by the Mayo Clinic Microarray and Mo-of a mixed 129C57BL/6 genetic background (to exclude effects of genetic
lecular Epidemiology shared facility as previously described in detail (Stegallbackground factors on tumor latency and penetrance). Mice were observed
et al., 2002). The initial analysis was performed using Affymetrix Microarraydaily for signs of poor health. Sick mice were sacrificed and screened for
Suite 5.0 with the default settings. The Data Mining Tool (DMT) programtumors. Survival curves were prepared using GraphPad Prism software.
was used to further select genes that were present in all samples being
compared and were differentially expressed by two or more fold (up- orPCR genotyping of mice
downregulated). Probe sets scored as absent were excluded from the analy-CBP, CBPflox, and CBP alleles were also genotyped by PCR. Primers
sis. Signal values for the selected genes were clustered and heat mapsused were CBP-F1 (5-GGGGAAATTTTG GCTGGCAAG-3) and CBP-R1
generated using Cluster and TreeView 1.6 software.(5-CTGCTCTACCTAAATTCCCAG-3). These primers produce 1250, 1100,
and 970 bp fragments for the CBP, CBPflox, and CBP alleles, respectively.
Quantitative RT-PCRp53 and p27Kip1 were identified according to previously described PCR proto-
cDNA was generated from 200 ng of total RNA using SuperScript II RNasecols (Fero et al., 1996; Jacks et al., 1994). The MMTV-Cre transgenic locus
H reverse transcriptase and 9-mer random primers. Primer sequences andwas identified as described (Wagner et al., 1997).
details of the real-time RT-PCR analysis are described in the Supplemental
Experimental Procedures at http://www.cancercell.org/cgi/content/full/5/2/
Tumor collection and histopathology
177/DC1.
Moribund animals were sacrificed and major organs screened for overt
tumors using a dissection microscope. Tumors were harvested and con-
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